Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives

2018 ◽  
Vol 19 (4) ◽  
pp. 358-367 ◽  
Author(s):  
Hui Wang ◽  
Qingzhu Yang ◽  
Q. Ping Dou ◽  
Huanjie Yang
Keyword(s):  
Proteasome Inhibitors ◽  
Current Status ◽  
Anticancer Therapeutics

scholarly journals Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Hiroko Nishida ◽  
Taketo Yamada
Keyword(s):  
Multiple Myeloma ◽  
Treatment Options ◽  
Proteasome Inhibitors ◽  
Novel Agents ◽  
Current Status ◽  
Antibody Drug Conjugate ◽  
The Past ◽  
Deacetylase Inhibitor ◽  
Car T ◽  
Immune Therapies

The treatment options in multiple myeloma (MM) has changed dramatically over the past decade with the development of novel agents such as proteasome inhibitors (PIs); bortezomib and immunomodulatory drugs (IMiDs); thalidomide, and lenalidomide which revealed high efficacy and improvement of overall survival (OS) in MM patients. However, despite these progresses, most patients relapse and become eventually refractory to these therapies. Thus, the development of novel, targeted immunotherapies has been pursued aggressively. Recently, next-generation PIs; carfilzomib and ixazomib, IMiD; pomalidomide, histone deacetylase inhibitor (HDADi); panobinostat and monoclonal antibodies (MoAbs); and elotuzumab and daratumumab have emerged, and especially, combination of mAbs plus novel agents has led to dramatic improvements in the outcome of MM patients. The field of immune therapies has been accelerating in the treatment of hematological malignancies and has also taken center stage in MM. This review focuses on an overview of current status of novel MoAb therapy including bispecific T-cell engager (BiTE) antibody (BsAb), antibody-drug conjugate (ADC), and chimeric antigen receptor (CAR) T cells, in relapsed or refractory MM (RRMM). Lastly, investigational novel MoAb-based therapy to overcome immunotherapy resistance in MM is shown.

scholarly journals PARP inhibitors: current status and implications for anticancer therapeutics

2013 ◽  
Vol 8 (1) ◽  
pp. 46 ◽  
Author(s):  
Hadi Usmani ◽  
Syed Hussain ◽  
Asfandyar Sheikh
Keyword(s):  
Parp Inhibitors ◽  
Current Status ◽  
Anticancer Therapeutics

Current status of special planetary and lunar theories and ephemerides

1966 ◽  
Vol 25 ◽  
pp. 266-267
Author(s):  
R. L. Duncombe
Keyword(s):  
Observational Data ◽  
Current Status ◽  
Numerical Errors

An examination of some specialized lunar and planetary ephemerides has revealed inconsistencies in the adopted planetary masses, the presence of non-gravitational terms, and some outright numerical errors. They should be considered of temporary usefulness only, subject to subsequent amendment as required for the interpretation of observational data.

Current Status of Solid-State X-Ray Systems

1985 ◽  
Vol 43 ◽  
pp. 158-161
Author(s):  
Martin Peckerar ◽  
Anastasios Tousimis
Keyword(s):  
Solid State ◽  
Electric Fields ◽  
Spectral Lines ◽  
Current Status ◽  
Mobile Charge ◽  
Electron Hole ◽  
X Ray ◽  
Sensing Systems ◽  
Transmission Electron ◽  
Electron Microscopes

Solid state x-ray sensing systems have been used for many years in conjunction with scanning and transmission electron microscopes. Such systems conveniently provide users with elemental area maps and quantitative chemical analyses of samples. Improvements on these tools are currently sought in the following areas: sensitivity at longer and shorter x-ray wavelengths and minimization of noise-broadening of spectral lines. In this paper, we review basic limitations and recent advances in each of these areas. Throughout the review, we emphasize the systems nature of the problem. That is. limitations exist not only in the sensor elements but also in the preamplifier/amplifier chain and in the interfaces between these components.Solid state x-ray sensors usually function by way of incident photons creating electron-hole pairs in semiconductor material. This radiation-produced mobile charge is swept into external circuitry by electric fields in the semiconductor bulk.

Electron-deficient boron-based catalysts for C–H bond functionalisation

2021 ◽  
Author(s):  
Yuanhong Ma ◽  
Shao-Jie Lou ◽  
Zhaomin Hou
Keyword(s):  
Review Article ◽  
Current Status ◽  
Comprehensive Overview

This review article provides a comprehensive overview to recognise the current status of electron-deficient boron-based catalysis in C–H functionalisations.

Proteasome inhibitors as therapeutics

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson
Keyword(s):  
Multiple Myeloma ◽  
Drug Class ◽  
Proteasome Inhibitors ◽  
Cell Cycle Regulators ◽  
Current State ◽  
Intracellular Mechanism ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway ◽  
Hodgkin's Lymphomas ◽  
Clinical Research Data

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.

Sign in / Sign up

Export Citation Format

Share Document